![Jeffrey Finer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeffrey Finer
Founder at
SEPTERNA, INC.
Net worth: 26 M $ as of 2026-06-29
Profile
Jeffrey T.
Finer is the founder of Septerna, Inc., established in 2019, where the title held is Chief Executive Officer & Director.
Current jobs include Director at Transcriptic, Inc. since 2018; Independent Director at Strateos, Inc. since 2022; Venture Partner at Third Rock Ventures LLC since 2016; and Board Member at Ambys Medicines, Inc. since 2019.
Former jobs include Director at Cytokinetics, Inc. from 1998 to 2007; Director at Maze Therapeutics, Inc.; Vice President at Five Prime Therapeutics, Inc. from 2007 to 2011; Vice President-Molecular & Cellular Biology at Innoviva, Inc.; and Vice President at Theravance Biopharma, Inc. from 2014 to 2016.
Education history includes a doctorate from Stanford University School of Medicine conferred in 1995 and an undergraduate degree from Massachusetts Institute of Technology conferred in 1988.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SEPTERNA, INC. 1.72% | 2026-04-28 | 775,408 ( 1.72% ) | 26 M $ | 2026-06-29 |
Jeffrey Finer active positions
| Companies | Position | Start |
|---|---|---|
| SEPTERNA, INC. | Founder | 2019-11-30 |
Transcriptic, Inc.
 Transcriptic, Inc. Medical SpecialtiesHealth Technology Designs, develops and builds lab automaton and virtualization technology | Director/Board Member | 2018-05-09 |
Strateos, Inc.
 Strateos, Inc. Packaged SoftwareTechnology Services Develops remote access laboratories and lab control software for life science discovery | Director/Board Member | 2022-03-09 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Private Equity Investor | 2015-12-31 |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Develops regenerative medicine therapies for serious liver diseases | Director/Board Member | 2018-12-31 |
Former positions of Jeffrey Finer
| Companies | Position | End |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Private Equity Investor | 2016-01-01 |
| FIVE PRIME THERAPEUTICS, INC. | Private Equity Investor | 2011-08-01 |
| CYTOKINETICS, INCORPORATED | Private Equity Investor | 2007-01-01 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Director/Board Member | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Jeffrey Finer
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
86
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
Cytokinetics, Inc.
 Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Innoviva, Inc.
 Innoviva, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that manufactures respiratory drugs | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
Transcriptic, Inc.
Transcriptic, Inc. Medical SpecialtiesHealth Technology Designs, develops and builds lab automaton and virtualization technology | Health Technology |
Theravance Biopharma, Inc.
 Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Develops regenerative medicine therapies for serious liver diseases | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
Strateos, Inc.
Strateos, Inc. Packaged SoftwareTechnology Services Develops remote access laboratories and lab control software for life science discovery | Technology Services |
Septerna, Inc.
 Septerna, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor oral small molecule products for the treatment of hypoparathyroidism | Health Technology |
- Stock Market
- Insiders
- Jeffrey Finer
